vaginal candidiasis. Candidiasis of vulva and vagina
Conditions
Interventions
Intervention 1: Intervention-3 doses 500mg meal Garsin tablet for 7 days. Intervention 2: Control- single dose 150 mg Fluconazole meal capsule.
Treatment - Drugs
Intervention-3 doses 500mg meal Garsin tablet for 7 days
Control- single dose 150 mg Fluconazole meal capsule
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 44 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Women were 18-44 years old and were married; They had a single sexual partner and they themselves were the only sexual partner of their respective spouse; They had not used antibiotics, immunosuppressive drugs, or vaginal drugs 14 days before the study; They did not suffer from trichomonal vaginitis, bacterial vaginitis, or cervicitis based on direct smear, which was controlled by examining the patient's discharge; They were not at pregnancy or breast-feeding stage; They were not menopause (priority of not being menopause was higher than age criterion, i.e. They must have been non-menopause even if they were younger than 49 years old); They had not previously suffered from known medical diseases such as diabetes, immune system attenuating diseases (such as AIDS) or use of immunosuppressive drugs, auto-immune diseases, coagulation disorders, and epilepsy; They were not menstruated, and had no bleeding or breakthrough bleeding when they visited the clinics; candidiasis culture was in agreement with clinical symptoms and patient's complaints. Exclusion ceiteria: pregnancy in study time table; emergency use of antibiotic in study time and druges intulerance.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginitis. Timepoint: Four to 7 days ofter completion of the treatment period. Method of measurement: Accomplished demographic information questionnaire and clinical performance checklist, clinical observation-pH value vaginal discharge and direct microscopy examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEbrahimi-Farzaneh
Clinical and treatment net
Outcome results
None listed